Evidence map›Paper›PMID 40600426›Full record

ReviewNanomedicine (London, England)2025

KRAS mutation-driven enhanced macropinocytosis: using albumin as a trojan horse for delivering nanomedicine.

Drishti Rathod, Mukti Vats, Poonam Gawali, Osaretin Otagho, Bhoomi Dholariya, Ketan Patel

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Drishti RathodCollege of Pharmacy and Health Sciences, St. John's University, Queens, NY, USA.
Mukti VatsCollege of Pharmacy and Health Sciences, St. John's University, Queens, NY, USA.
Poonam GawaliCollege of Pharmacy and Health Sciences, St. John's University, Queens, NY, USA.
Osaretin OtaghoCollege of Pharmacy and Health Sciences, St. John's University, Queens, NY, USA.
Bhoomi DholariyaCollege of Pharmacy and Health Sciences, St. John's University, Queens, NY, USA.
Ketan PatelCollege of Pharmacy and Health Sciences, St. John's University, Queens, NY, USA.

Funding

Combination of tumor targeted therapy with stroma modulating agent for PDACR16GM145556 · NIGMS · ST. JOHN'S UNIVERSITY · PI Ketankumar D. Patel · 2023 to 2026
$750k
NIGMS NIH HHS R16 GM145556
6 · The paper itself

Abstract

Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS), the most mutated oncogene, drives tumoral progression by leveraging macropinocytosis. This nutrient uptake pathway is responsible for promoting the relentless growth of KRAS-mutant tumoral cells while also unlocking a new frontier for the exploration of innovative therapeutic approaches. Leveraging KRAS-driven macropinocytosis, researchers are instigating advanced nanoparticulate drug delivery systems, including albumin nanoparticles and DNA- and RNA-loaded lipid nanoparticles. We emphasize the emerging strategies to exploit KRAS-macropinocytosis-albumin crosstalk presenting a promising avenue for the delivery of albumin nanoparticles in cancer therapy.

Indexed as

AlbuminsNeoplasmsPinocytosisProto-Oncogene Proteins p21(ras)AnimalsDrug Delivery SystemsHumansMutationNanomedicineNanoparticlesAlbuminsKRAS protein, humanProto-Oncogene Proteins p21(ras)albuminKRAS mutationmacropinocytosisnanoparticlestargeted delivery

Identifiers

PMID40600426
PMCPMC12239804

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.